Literature DB >> 15825002

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

A Mangili1, I Bica, D R Snydman, D H Hamer.   

Abstract

We describe a patient who developed daptomycin-resistant, methicillin-resistant Staphylococcus aureus (MRSA) during an episode of presumed septic thrombophlebitis of the portal vein. Although daptomycin is an alternative agent for treatment of drug-resistant gram-positive bacterial infections, development of resistance during prolonged use may occur with MRSA bacteremia from a persistent focus.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15825002     DOI： 10.1086/428616

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  69 in total

1.  Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  C Garrigós; O Murillo; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus.

Authors:  Aileen Rubio; Mary Conrad; Robert J Haselbeck; Kedar G C; Vickie Brown-Driver; John Finn; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

3.  Assessment of two commercial susceptibility test methods for determination of daptomycin MICs.

Authors:  James H Jorgensen; Sharon A Crawford
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 4.  Antimicrobial stewardship programs in health care systems.

Authors:  Conan MacDougall; Ron E Polk
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 5.  Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.

Authors:  G M Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

6.  De novo daptomycin nonsusceptibility in a clinical isolate.

Authors:  Emil P Lesho; Glenn W Wortmann; David Craft; Kimberly A Moran
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

7.  Ethical conflicts in public health research and practice: antimicrobial resistance and the ethics of drug development.

Authors:  Allison E Aiello; Nicholas B King; B Foxman
Journal:  Am J Public Health       Date:  2006-10-03       Impact factor: 9.308

8.  Mechanisms of resistance to daptomycin in Enterococcus faecium.

Authors:  Clemente I Montero; Frida Stock; Patrick R Murray
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

9.  daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Warren E Rose; Steven N Leonard; George Sakoulas; Glenn W Kaatz; Marcus J Zervos; Anjly Sheth; Christopher F Carpenter; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2007-11-12       Impact factor: 5.191

10.  Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus.

Authors:  Anu Daniel; Chad Euler; Mattias Collin; Peter Chahales; Kenneth J Gorelick; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.